Discovery of cytochrome P450 1B1 inhibitors as new promising anti-cancer agents.
Human cytochrome P450 (CYP)1B1 is a major enzyme for carcinogenic estrogen metabolism and involved in the metabolic activation of procarcinogens of the polycyclic aromatic hydrocarbons (PAHs). CYP1B1 is known to be expressed at a high frequency in various human cancers, but not in normal tissues. It also plays an important role in the metabolism of various anti-cancer drugs. These findings suggest inhibition of CYP1B1 as a new oncological therapeutic strategy. Several natural and synthetic compounds have been studied in an effort to find the isoform-specific inhibitors of the CYP1 subfamily. A survey of the inhibitors of CYP1B1 and other related inhibitors of the CYP1 subfamily is provided in this review.
Chun
Young-Jin
YJ
College of Pharmacy, Chungang University, 221 Huksuk, Dongjak, Seoul 156-756, Korea.
Kim
Sanghee
S
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001189:Aryl Hydrocarbon Hydroxylases / Q000037:antagonists & inhibitors* / Q000494:pharmacology*; D065633:Cytochrome P-450 CYP1B1; D005260:Female; D005544:Forecasting; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012680:Sensitivity and Specificity; D013329:Structure-Activity Relationship
D000970:Antineoplastic Agents; D001189:Aryl Hydrocarbon Hydroxylases; C585496:CYP1B1 protein, human; D065633:Cytochrome P-450 CYP1B1